CSP Exam Test With Answers
1. PDC calculation: PDC = (# of unique days with supply / number of days in a
period) x 100
2. Which medication is a Jak inhibitor?
a. Humira (adalimumab)
b. Orencia (abatacept)
c. Actemra (toclizumab)
d. Xeljanz (tofacitinib): d. Xeljanz (tofacitinib)
3. Which medication can elevate cholesterol?
a. Actemra (toclizumab)
b. Enbrel (etanercept)
c. Simponi (golimumab)
d. Kineret (anakinra): a. Actemra (toclizumab)
4. Which shingles vaccine is safe to administer with TNF inhibitors?
a. Adacel
b. Zostavax
c. Shingrix
d. Varivax: c. Shingrix
5. Most biologics increase the risk of infections, which of the following also
increases the risk of
neutropenia?
a. Rituxin (rituximab)
b. Taltz (ixekizumab)
c. Remicade (infliximab)
d. Cimzia (certolizumab pegol): b. Taltz (ixekizumab)
6. Which psoriasis medication does not require screening for tuberculosis?
a. Stelara (ustekinumab)
b. Otezla (apremilast)
c. Cocentyx (seculinumab)
d. Humira (adalimumab): b. Otezla (apremilast)
7. What is the standard starting dose for Taltz (ixekizumab) when used to treat
psoriatic arthritis?
a. 160mg subcutaneously once, followed by 80mg subcutaneously at weeks
2, 4, 6, 8, 10
and 12; then 80mg subcutaneously every 4 weeks
b. 160mg subcutaneously once, followed by 80mg subcutaneously every 4
weeks
c. 160mg subcutaneously once, followed by 80mg subcutaneously every week
for 4 weeks,
then 80mg every 4 weeks
, CSP Exam Test With Answers
d. 160mg subcutaneously once, followed by 80mg subcutaneously every other
week: b. 160mg subcutaneously once, followed by 80mg subcutaneously every 4
weeks
8. A 45 y/o, 200lb patient is struggling with severe dermatitis and the provider
wants to potentially
start a biologic. Which medication would you recommend?
a. Protopic (tacrolimus)
b. Humira (adalimumab)
c. Stelara (ustekinumab)
d. Dupixent (dupilumab): d. Dupixent (dupilumab)
9. A 56 y/o, 140lb patient with psoriasis will be starting Stelara (ustekinumab),
but the provider
wants to verify the dosing of the medication. What starting dose would you
recommend?
a. Inject 45 mg subcutaneously at weeks 0 and 4, followed by 45 mg every 12
weeks
b. Inject 90 mg subcutaneously at weeks 0 and 4, followed by 90 mg every 12
weeks
c. Infuse 260 mg IV over at least 1 hour as a single dose, followed 8 weeks later
with 90 mg
subcutaneously every 8 weeks
d. Infuse 520 mg IV over at least 1 hour as a single dose, followed 8 weeks later
with 90 mg
subcutaneously every 8 weeks: a. Inject 45 mg subcutaneously at weeks 0 and
4, followed by 45 mg every 12 weeks
10. Which of the following oral oncology medications does NOT require using
caution in patients
with hepatic impairment?
a. Votrient (pazopanib)
b. Ibrance (palbociclib)
c. Zytiga (abiraterone acetate)
d. Tykerb (lapatinib): b. Ibrance (palbociclib)
11. Which side effect listed below is NOT a side effect of Zytiga (abiraterone
acetate)?
a. Edema
b. Hot flush
c. Hepatotoxicity
d. Mucositis: d. Mucositis
1. PDC calculation: PDC = (# of unique days with supply / number of days in a
period) x 100
2. Which medication is a Jak inhibitor?
a. Humira (adalimumab)
b. Orencia (abatacept)
c. Actemra (toclizumab)
d. Xeljanz (tofacitinib): d. Xeljanz (tofacitinib)
3. Which medication can elevate cholesterol?
a. Actemra (toclizumab)
b. Enbrel (etanercept)
c. Simponi (golimumab)
d. Kineret (anakinra): a. Actemra (toclizumab)
4. Which shingles vaccine is safe to administer with TNF inhibitors?
a. Adacel
b. Zostavax
c. Shingrix
d. Varivax: c. Shingrix
5. Most biologics increase the risk of infections, which of the following also
increases the risk of
neutropenia?
a. Rituxin (rituximab)
b. Taltz (ixekizumab)
c. Remicade (infliximab)
d. Cimzia (certolizumab pegol): b. Taltz (ixekizumab)
6. Which psoriasis medication does not require screening for tuberculosis?
a. Stelara (ustekinumab)
b. Otezla (apremilast)
c. Cocentyx (seculinumab)
d. Humira (adalimumab): b. Otezla (apremilast)
7. What is the standard starting dose for Taltz (ixekizumab) when used to treat
psoriatic arthritis?
a. 160mg subcutaneously once, followed by 80mg subcutaneously at weeks
2, 4, 6, 8, 10
and 12; then 80mg subcutaneously every 4 weeks
b. 160mg subcutaneously once, followed by 80mg subcutaneously every 4
weeks
c. 160mg subcutaneously once, followed by 80mg subcutaneously every week
for 4 weeks,
then 80mg every 4 weeks
, CSP Exam Test With Answers
d. 160mg subcutaneously once, followed by 80mg subcutaneously every other
week: b. 160mg subcutaneously once, followed by 80mg subcutaneously every 4
weeks
8. A 45 y/o, 200lb patient is struggling with severe dermatitis and the provider
wants to potentially
start a biologic. Which medication would you recommend?
a. Protopic (tacrolimus)
b. Humira (adalimumab)
c. Stelara (ustekinumab)
d. Dupixent (dupilumab): d. Dupixent (dupilumab)
9. A 56 y/o, 140lb patient with psoriasis will be starting Stelara (ustekinumab),
but the provider
wants to verify the dosing of the medication. What starting dose would you
recommend?
a. Inject 45 mg subcutaneously at weeks 0 and 4, followed by 45 mg every 12
weeks
b. Inject 90 mg subcutaneously at weeks 0 and 4, followed by 90 mg every 12
weeks
c. Infuse 260 mg IV over at least 1 hour as a single dose, followed 8 weeks later
with 90 mg
subcutaneously every 8 weeks
d. Infuse 520 mg IV over at least 1 hour as a single dose, followed 8 weeks later
with 90 mg
subcutaneously every 8 weeks: a. Inject 45 mg subcutaneously at weeks 0 and
4, followed by 45 mg every 12 weeks
10. Which of the following oral oncology medications does NOT require using
caution in patients
with hepatic impairment?
a. Votrient (pazopanib)
b. Ibrance (palbociclib)
c. Zytiga (abiraterone acetate)
d. Tykerb (lapatinib): b. Ibrance (palbociclib)
11. Which side effect listed below is NOT a side effect of Zytiga (abiraterone
acetate)?
a. Edema
b. Hot flush
c. Hepatotoxicity
d. Mucositis: d. Mucositis
